South Korea is moving to bring abortion pills into its formal medical system, addressing a regulatory gap that has persisted for years after the country stopped criminalizing abortion but failed to establish a comprehensive framework for medication abortion.
The move puts South Korea on a markedly different starting point from the U.S., where mifepristone has been federally approved since 2000 and can be prescribed through certified providers and dispensed through certified pharmacies. The U.S. Food and Drug Administration permits mifepristone, used with misoprostol, through 10 weeks of pregnancy. South Korea plans to begin more cautiously, limiting use to pregnancies of up to nine weeks and keeping both prescribing and dispensing inside hospitals during the first two years.
That difference makes the Korean rollout relevant beyond the country’s abortion debate. Seoul is effectively building a regulated market and distribution system for a medicine that has remained outside ordinary legal medical access even after abortion itself was decriminalized. The first phase will largely exclude retail pharmacies, before the government plans to move toward physician prescriptions and pharmacy dispensing once safety and regulatory systems are established.
The gap dates to a 2019 ruling by South Korea’s Constitutional Court, which found the country’s criminal abortion provisions unconstitutional. The provisions became invalid at the beginning of 2021, effectively decriminalizing abortion, but lawmakers did not replace them with a comprehensive regulatory framework governing access to abortion services and medication.
That left South Korea in an unusual position. Abortion was no longer criminalized under the old provisions, yet women seeking medication abortion did not have a fully established domestic system through which approved drugs could routinely be prescribed and dispensed. The government said the regulatory vacuum has pushed some women toward unverified or potentially unsafe methods.
Prime Minister Han Seong-sook said Wednesday that safety would be the government’s priority as it introduces Mifegyne, which contains the active ingredient mifepristone.
During the initial two year period, doctors will prescribe and dispense the medication directly at medical institutions. The government intends to allow pharmacies to take over dispensing later if the necessary safeguards are in place.
Han said the policy should not be interpreted as an effort to encourage abortion, adding that the government also takes concerns about the value of life seriously. She described the measure instead as an attempt to move abortion care into a supervised medical system and reduce reliance on unverified alternatives.
The initiative follows President Lee Jae-myung’s instruction in July to examine whether abortion medication could be introduced. South Korea’s drug regulator is reviewing an application to import abortion pills for use within 63 days of pregnancy, while health authorities are preparing safety management and clinical guidelines for their introduction.
The rollout will also create a new regulatory pathway that drug suppliers, hospitals and eventually pharmacies will have to navigate. The government has not identified a commercial beneficiary or provided an estimate of the potential market, making it premature to attach the policy to any particular company. What is clear is that South Korea is moving a form of reproductive health care that has existed in a legal and regulatory gray zone into the country’s mainstream health system, seven years after the court decision that started the process.
